TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ages 21 to 75 inclusive. Female subjects must be of non-childbearing potential;~* Has at the Screening Visit a serum uric acid ≥ 6 mg/dL, with or without a history of gout;~* The use of allopurinol, febuxostat (Uloric®), or probenecid as uric acid-lowering therapy is permissible if dosing has been stable for at least the month prior to the Screening Visit~* Has adequate venous access and able to receive IV therapy;~* Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study;~Exclusion Criteria:~* Prior exposure to any experimental or marketed uricase;~* History of any allergy to pegylated products,~* Glucose-6-phosphate dehydrogenase deficiency or known catalase deficiency;~* History of hematological or autoimmune disorders, is immunosuppressed or immunocompromised;~* Has participated in a clinical trial within 30 days of the Screening;

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SEL-037 (pegsiticase) (Type: EXPERIMENTAL): Pegylated uricase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 70 years or greater~* Cytologic / histologic diagnosis ovarian cancer~* Stage of disease at diagnosis IC -IV~* Performance status (ECOG) \< 3~* Indication for chemotherapy treatment~* Written informed consent~Exclusion Criteria:~* Previous or concomitant malignant neoplasia (not including basocellular or spinocellular skin carcinoma or in-situ carcinoma of the uterine cervix, provided they are being adequately treated)~* Cerebral metastases~* Neutrophils \< 1000/mm3, platelets \< 100000/mm3, hemoglobin \< 8g/dl~* Creatinine \> o = 1.25 times the upper normal limit~* GOT or GPT \> o = 1.25 times the upper normal limit, except in case of liver metastases)~* Patient's inability to comply with followup

- Gender: FEMALE
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SINGLE ARM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of a Predictive Model of Bowel Preparation Based on Procedure-related Factors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18\~75 years~* Patients undergoing morning colonoscopy~Exclusion Criteria:~* colon resection;~* suspected bowel obstruction;~* moderate or severe complications related to drinking the 1st or 2rd dose of PEG~* hemodynamically unstable;~* lactating or pregnant women;~* no need to reach the ileocecal segment~* unwilling to provided informed content.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- control group (Type: NO_INTERVENTION): Colonoscopy was performed in the control group directly.
- model-based interference group (Type: EXPERIMENTAL): Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group colonoscopy directly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject aged 12 to \<15 months or 18 to \<24 months during sentinel-cohort enrollment, Or,12 to \<24 months during expanded-cohort enrollment.~* Subjects must have received all vaccinations in the relevant National Immunization Program (NIP) for their age group.~* Subject is determined to be in good health by medical history, physical examination, and judgment of the investigator.~Exclusion Criteria:~* Previous vaccination with any meningococcal serogroup B vaccine.~* Previous vaccination with HAV vaccine, or requirement to receive nonstudy HAV vaccine during Stage 1 of the study.~* Contraindication to vaccination with any HAV vaccine or known latex allergy.~* A previous anaphylactic reaction to any vaccine or vaccine-related component.~* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.~* A known or suspected disorder of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B-cell function or those receiving systemic immunosuppressive therapy. Subjects with terminal complement deficiency may be included.~* History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.~* Significant neurologic disorder or history of seizure (excluding simple febrile seizure).~* Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination until the end of Stage 1.~* Current chronic use of systemic antibiotics.~* Received any investigational drugs, vaccines or devices within 28 days before administration of the first study vaccination and/or during study participation.~* Any neuroinflammatory or autoimmune condition, including but not limited to transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- rLP2086 vaccine (Type: EXPERIMENTAL): Arm stratified by age:~≥12 to \<18 months and ≥18 to \<24 months
- Control (Type: ACTIVE_COMPARATOR): Arm stratified by age:~≥12 to \<18 months and ≥18 to \<24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of FXS by clinical evaluation and confirmed by FMR1-DNA testing with presence of full mutation or mosaicism for the full mutation. Prior DNA testing reports will be accepted, when available.~* Age between 13 to 35 years inclusive at the time of informed consent.~* Male or female~* CGI-Severity Score of 4 or greater, indicative of moderate or greater severity of behavioural problems. This is a 7-point scale of clinical global impression of severity that the clinician fills out after considering all the available information on the patient, including the parent history, the examination in clinic, reports from the school and other sources.~* Score of 9 or greater on the Aberrant Behaviour Checklist - Irritability Scale (top 50th %-tile). The ABC is a global behaviour checklist implemented for the measurement of drug and other treatment effects in mentally impaired individuals. It is made up of 5 empirically derived dimensions including irritability, lethargy/withdrawal, inappropriate speech, hyperactivity, and stereotypic behaviour based on 58 items that describe various behavioural problems.~* Availability of parent and/or caregiver for all clinic visits and assessments.~* English language fluency and reading level of 6th grade or greater in one caregiver.~Exclusion Criteria:~* Allergy to minocycline.~* Kidney disease or elevated renal function tests.~* Liver disease or elevated liver function tests.~* Participants with neutropenia, anemia, or thrombocytopenia.~* History of systemic lupus erythematosus or screening anti-nuclear antibody (ANA) titre of \>1:40, as minocycline may cause a lupus-like reaction.~* Individuals who do not have a mother or caregiver who is willing to participate in the clinic visits.~* Individuals who are pregnant or at risk to become pregnant, specifically sexually active females will be excluded.~* Presence of persistent psychotic symptoms~* Subjects with symptom severity likely judged to endanger personal safety or safety of others.~* History of systemic lupus erythematosus or screening anti-nuclear antibody (ANA) titre of \>1:40, as minocycline may cause a lupus-like reaction.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- minocyline 50 mg or 100 mg PO BID (Type: EXPERIMENTAL): open label treatment with minocycline low or high dose, 50 mg or 100 mg PO (by mouth) BID (twice a day), added to existing medication regimen for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of CES on Parasympathetic Tone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteer~Exclusion Criteria:~* daily psychotropic medication,~* use of beta blocker,~* pacemaker,~* other metal in body,~* history of seizures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Dose sequence: Sham, Low, High (Type: OTHER): Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -1 milliamp stimulation intensity, Day 3 - 2milliamp stimulation intensity
- Dose sequence: Sham, High, Low (Type: OTHER): Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -2 milliamp stimulation intensity, Day 3 - 1milliamp stimulation intensity
- Dose sequence: Low, Sham, High (Type: OTHER): Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 -Sham stimulation; Day 3 - 2milliamp stimulation intensity
- Dose sequence: Low, High, Sham (Type: OTHER): Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 - 2milliamp stimulation intensity; Day 3 - Sham stimulation
- Dose sequence: High, Sham, Low (Type: OTHER): Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - Sham stimulation; Day 3 - 1 milliamp stimulation intensity
- Dose sequence: High, Low, Sham (Type: OTHER): Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - 1 milliamp stimulation intensity; Day 3 - Sham stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SH T00186 in the Treatment of Primary Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Otherwise healthy female patients with moderate to severe primary dysmenorrhea~* Prospective self-rated sum pain score of \>/= 8 during the 2 baseline cycles~* Age between 18 and 40 years (inclusive) with smoking habits as follows:~  * between 18 and 30 years of age. daily cigarette consumption not above 10~ * above 30 years of age, no smoking~Exclusion Criteria:~* Current signs of history of any forms of secondary dysmenorrhea~* Any concomitant disease of condition that requires any intake of analgesic medication~* Occurrence of less than six menstrual cycles before Visit 1 following delivery, abortion, or lactation~* Clinically significant depression

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurokinin Receptor Antagonist Associated to Ondansetron in PONV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* high risk patients for nausea and vomiting~Exclusion Criteria:~* cardiovascular disease, or hypersensibility to any of the drugs involved in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- aprepitant (Type: EXPERIMENTAL): aprepitant 80 mg one hour before surgery
- placebo (Type: PLACEBO_COMPARATOR): oral placebo one hour before surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female 12 years of age or older with a minimum of 2 years of previous history of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.~* Signed informed consent form. For patients under the age of majority the parent or legal guardian should sign the consent form and the child will be required to sign a patient assent form.~* Documented positive allergic skin test to local pollen, performed within the past 12 months.~* A score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) with a minimum score of at least 2 for nasal congestion and a minimum score of at least 2 for one of the remaining 3 symptoms.~Exclusion Criteria:~* Females who are pregnant, lactating or likely to become pregnant during the study.~* History of asthma over the previous two years that required chronic therapy (with the exception of occasional acute or mild exercise induced asthma).~* Patients with some nasal conditions, or with clinically significant nasal deformity or any recent nasal surgery or trauma that has not completely healed.~* Upper respiratory tract infection or any untreated infections within the previous 30 days.~* Patient has started immunotherapy/changed the dose within 30 days of starting the study or has desensitization therapy to the seasonal allergen that is causing the allergic rhinitis within the previous 6 months.~* Patients with a history of tuberculosis, or with the presence of glaucoma, cataracts, ocular herpes simplex, conjunctivitis or other eye infection not related to the diagnosis of seasonal allergic rhinitis within 14 days of enrollment.~* The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.~* Any known hypersensitivity to mometasone, other steroids or any of the components of the study nasal spray.~* Planned travel outside of the local area for more than 2 consecutive days or 3 days in total.~* The patient has a history of alcohol or drug abuse.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test (Type: EXPERIMENTAL): Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
- Reference (Type: ACTIVE_COMPARATOR): Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo nasal spray administered once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Colchicine Plus Phenolic Monoterpenes to Treat COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Defined cases of COVID-19 based on laboratory and/or radiological and clinical manifestation~Exclusion Criteria:~* Age \<10, Pregnancy, Sever kidney dysfunction, Previous history of allergy to Colchicine, not willing to sign informed consent form

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Treatment (Type: EXPERIMENTAL): Patients diagnosed with COVID-19 which receive the standard treatment national guideline
- Colchicine and Herbal Phenolic Monoterpene Fractions (Type: EXPERIMENTAL): Patients diagnosed with COVID-19 which receive the standard treatment national guideline plus Colchicine and Herbal Phenolic Monoterpene Fractions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Type 2 Diabetes and Ambulatory Surgery Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18-80 years old~* Established diagnosis of type 2 diabetes mellitus~* Undergoing ambulatory surgery.~* Receiving OHA treatment for diabetes .~Exclusion Criteria:~* Treatment of insulin monotherapy~* Treatment with combination of oral hypoglycemic agents such as Thiazolidinediones-Repaglimide (Prandin), Rosiglitazone (Avandia), Pioglitazone (Actos).~* Renal Insufficiency with Serum Creatinine \> 2mg/dl~* Decompensated congestive heart failure decompensated congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Oral hypoglycemic agent continue (Type: EXPERIMENTAL): Metformin continue on the day of surgery
- Oral hypoglycemic agent discontinue (Type: ACTIVE_COMPARATOR): Metformin discontinue on the day of surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children undergoing tonsillectomy with and without adenoidectomy and myringotomy and tube insertion~* ASA 1,2,3~* females who have started menses but have a negative urine pregnancy test~Exclusion Criteria:~* patients with known dysrhythmias,~* not recovering in the ICU~* developmental delay,~* autism communication disorder~* bleeding disorder~* PI discretion

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): Dexmedetomidine
- placebo (Type: PLACEBO_COMPARATOR): Normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperlipidemia~* Statin Intolerant~* Fasting LDL-C \> = 70 mg/dL Fasting TG \< = 400 mg/dL~Exclusion Criteria:~* Pregnant or breastfeeding females~* Cardiovascular or cerebrovascular event or procedure within 90 days~* Severe or life-threatening adverse events with past use of statins~* Poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bococizumab (PF-04950615;RN316) (Type: EXPERIMENTAL): Bococizumab (PF-04950615;RN316)
- Atorvastatin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete